{"eventGroups":[{"description":"Expanded and activated autologous NK cells (NKAEs) + chemotherapy (lenalidomide OR bortezomib).\n\nNKAE cells infusion: Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.\n\nLenalidomide: Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.\n\nBortezomib: bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.","id":"EG000","otherNumAffected":2,"otherNumAtRisk":5,"seriousNumAffected":2,"seriousNumAtRisk":5,"title":"NKAE Cells Infusion + Chemotherapy"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"Two patients had grade II neutropenia but none of them need dose adjustment.","organSystem":"Immune system disorders","sourceVocabulary":"CTCAE 3.0","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":5,"numEvents":2}],"term":"Neutropenia"}],"seriousEvents":[{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"The patient was suffering for gastrointestinal bleeding before enrollment.","organSystem":"Gastrointestinal disorders","sourceVocabulary":"CTCAE 3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5,"numEvents":1}],"term":"Gastrointestinal bleeding"},{"assessmentType":"NON_SYSTEMATIC_ASSESSMENT","notes":"This serious adverse event was due to multiple myeloma bone lesions.","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"CTCAE 3.0","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":5,"numEvents":2}],"term":"Vertebral compression"}],"timeFrame":"4 months during treatment with NKAE cells."}